scholarly journals Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients

JAMA ◽  
2016 ◽  
Vol 315 (13) ◽  
pp. 1354 ◽  
Author(s):  
Gonzalo Hernández ◽  
Concepción Vaquero ◽  
Paloma González ◽  
Carles Subira ◽  
Fernando Frutos-Vivar ◽  
...  
2020 ◽  
Author(s):  
Ajay Bhasin ◽  
Melissa Bregger ◽  
Mark Kluk ◽  
Peter Park ◽  
Joe Feinglass ◽  
...  

AbstractBackgroundThe importance of ambulatory hypoxia without resting hypoxia in COVID-19 is unknown. Ambulatory hypoxia without resting hypoxia may help objectively identify high-risk patients hospitalized with COVID-19. Interventions may be initiated earlier with sufficient lead-time between development of ambulatory hypoxia and other outcome measures.MethodsWe performed a retrospective study of adult patients hospitalized with COVID-19 from March 1, 2020 to October 30, 2020 in ten hospitals in an integrated academic medical system in the Chicagoland area. We analyzed patients who had daily ambulatory oximetry measurements, excluding patients who had first ambulatory oximetry measurements after the use of oxygen therapies (nasal cannula or advanced oxygen therapies). We determined the association of ambulatory hypoxia without resting hypoxia with the eventual need for nasal cannula or advanced oxygen therapies (defined as high flow nasal cannula, Bi-PAP, ventilator, or extracorporeal membrane oxygenation). We also calculated the time between development of ambulatory hypoxia and the need for oxygen therapies.ResultsOf 531 patients included in the study, 132 (24.9%) had ambulatory hypoxia. Presence of ambulatory hypoxia was strongly associated with subsequent use of nasal cannula (OR 4.8, 95% CI 2.8 – 8.4) and advanced oxygen therapy (IRR 7.7, 95% CI 3.4 – 17.5). Ambulatory hypoxia preceded nasal cannula use by a median 12.5 hours [IQR 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82].ConclusionAmbulatory hypoxia without resting hypoxia may serve as an early, non-invasive physiologic marker for the likelihood of developing moderate to severe COVID-19 and help clinicians triage patients and initiate earlier interventions.


2021 ◽  
Author(s):  
Paola Papoff ◽  
Elena Caresta ◽  
Stefano Luciani ◽  
Alessandra Pierangeli ◽  
Carolina Scagnolari ◽  
...  

2018 ◽  
Vol 18 (12) ◽  
pp. 1652-1653 ◽  
Author(s):  
Filippo Luca Fimognari ◽  
Massimo Rizzo ◽  
Olga Cuccurullo ◽  
Giovanna Cristiano ◽  
Roberto Ricchio ◽  
...  

2020 ◽  
Vol 12 (1) ◽  
pp. 1-5
Author(s):  
Ibtesam A. Hilmi ◽  
Philip C. Carullo ◽  
Dennis P. Phillips ◽  
Ezeldeen Abuelkasem

The physiologic benefits of high-flow nasal cannula (HFNC) therapy are well documented in the intensive care literature, yet only a handful of case reports describe its perioperative use. Our single center experience explored comprehensive applications of HFNC in the perioperative setting. Over a ten-month period, HFNC was used in the care of 85 medically complex patients either as an adjuvant or main oxygen therapy during induction of general anesthesia, maintenance of deep intraoperative sedation, and during early postoperative care. Here, we illustrate clinical scenarios in which HFNC therapy made patient care safer and describe a framework for integrating this technology into the anesthesia practice at our institution.


Sign in / Sign up

Export Citation Format

Share Document